Neoadjuvant hyperfractionated accelerated radiotherapy plus concomitant 5-fluorouracil infusion in locally advanced rectal cancer: A phase. study
dc.contributor.author | Gural, Zeynep | |
dc.contributor.author | Saglam, Sezer | |
dc.contributor.author | Yucel, Serap | |
dc.contributor.author | Kaytan-Saglam, Esra | |
dc.contributor.author | Asoglu, Oktar | |
dc.contributor.author | Ordu, Cetin | |
dc.contributor.author | Acun, Hediye | |
dc.contributor.author | Sharifov, Rasul | |
dc.contributor.author | Onder, Semen | |
dc.contributor.author | Kizir, Ahmet | |
dc.contributor.author | Oral, Ethem N. | |
dc.date.accessioned | 2023-02-21T12:38:47Z | |
dc.date.available | 2023-02-21T12:38:47Z | |
dc.date.issued | 2018-01-01 | |
dc.description.abstract | AIM To evaluate the efficacy and tolerability of neoadjuvant hyperfractionated accelerated radiotherapy (HART) and concurrent chemotherapy in patients with locally advanced infraperitoneal rectal cancer. METHODS A total of 30 patients with histopathologically confirmed T2-3/N0+ infraperitoneal adenocarcinoma of rectum cancer patients received preoperative 42 Gy/1.5 Gy/18 days/bid radiotherapy and continuous infusion of 5-fluorouracil (325 mg/m(2)). All patients were operated 4-8 wk after neoadjuvant concomitant therapy. RESULTS In the early phase of treatment, 6 patients had grade III- IV gastrointestinal toxicity, 2 patients had grade III-IV hematologic toxicity, and 1 patient had grade V toxicity due to postoperative sepsis during chemotherapy. Only 1 patient had radiotherapy-related late side effects, i.e., grade IV tenesmus. Complete pathological response was achieved in 6 patients (21\%), while near-complete pathological response was obtained in 9 (31\%). After a median follow-up period of 60 mo, the local tumor control rate was 96.6\%. In 13 patients, distant metastasis occurred. Disease-free survival rates at 2 and 5 years were 63.3\% and 53\%, and corresponding overall survival rates were 70\% and 53.1\%, respectively. CONCLUSION Although it has excellent local control and complete pathological response rates, neoadjuvant HART concurrent chemotherapy appears to not be a feasible treatment regimen in locally advanced rectal cancer, having high perioperative complication and intolerable side effects. Effects of reduced 5-fluorouracil dose or omission of chemotherapy with the aim of reducing toxicity may be examined in further studies. | |
dc.description.issue | 1 | |
dc.description.issue | JAN 15 | |
dc.description.pages | 40-47 | |
dc.description.volume | 10 | |
dc.identifier.doi | 10.4251/wjgo.v10.i1.40 | |
dc.identifier.uri | https://hdl.handle.net/11443/2427 | |
dc.identifier.uri | http://dx.doi.org/10.4251/wjgo.v10.i1.40 | |
dc.identifier.wos | WOS:000419892600005 | |
dc.publisher | BAISHIDENG PUBLISHING GROUP INC | |
dc.relation.ispartof | WORLD JOURNAL OF GASTROINTESTINAL ONCOLOGY | |
dc.subject | Hyperfractionated accelerated radiotherapy | |
dc.subject | Rectal cancer | |
dc.subject | Neoadjuvant chemoradiotherapy | |
dc.title | Neoadjuvant hyperfractionated accelerated radiotherapy plus concomitant 5-fluorouracil infusion in locally advanced rectal cancer: A phase. study | |
dc.type | Article |
Files
Original bundle
1 - 1 of 1
- Name:
- Neoadjuvant hyperfractionated accelerated radiotherapy plus concomitant 5-fluorouracil infusion in locally advanced rectal cancer A phase. study.pdf
- Size:
- 1.27 MB
- Format:
- Adobe Portable Document Format